Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
Revenue Growth Under PressureDecelerating
Percentile Rank79
5Y CAGR-16.8%
Studio
Year-over-Year Change

Year-over-year revenue growth rate

5Y CAGR
-16.8%/yr
Long-term compound
Percentile
P79
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
202521.31%
2024185.66%
202354.14%
2022-3.79%
2021-65.52%
202053.37%
2019-19.57%
20180.00%
20170.00%
20160.00%